Increased resistin in brain dead organ donors is associated with delayed graft function after kidney transplantation

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Oltean, Simona ^a,b   Pullerits, Rille ^a,c   Flodén, Anne ^a   Olausson, Michael ^a,d   Oltean, Mihai ^a,d  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCYTE CHEMOTACTIC PROTEIN 1; RESISTIN;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BLOOD LEVEL; BRAIN DEAD DONOR; CADAVER DONOR; CONTROLLED STUDY; DELAYED GRAFT FUNCTION; DISEASE ASSOCIATION; FEMALE; GRAFT RECIPIENT; HUMAN; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PROTEIN DETERMINATION; PROTEIN FUNCTION; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; BRAIN DEATH; CREATININE; DELAYED GRAFT FUNCTION; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; POSTOPERATIVE CARE; RESISTIN; ROC CURVE; TISSUE DONORS;

EID: 84884561691     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-233     Document Type: Article

References (42)

1. Koo DD, Welsh KI, McLaren AJ, Roake JA, Morris PJ, Fuggle SV. Cadaver versus living donor kidneys: impact of donor factors on antigen induction before transplantation. Kidney Int 1999, 56:1551-1559. 10.1046/j.1523-1755.1999.00657.x, 10504507.
2. Nijboer WN, Schuurs TA, van der Hoeven JA, Fekken S, Wiersema-Buist J, Leuvenink HG, Hofker S, Homan van der Heide JJ, van Son WJ, Ploeg RJ. Effect of brain death on gene expression and tissue activation in human donor kidneys. Transplantation 2004, 78:978-986. 10.1097/01.TP.0000135565.49535.60, 15480162.
3. Weiss S, Kotsch K, Francuski M, Reutzel-Selke A, Mantouvalou L, Klemz R, Kuecuek O, Jonas S, Wesslau C, Ulrich F, et al. Brain death activates donor organs and is associated with a worse I/R injury after liver transplantation. Am J Transplant 2007, 7:1584-1593. 10.1111/j.1600-6143.2007.01799.x, 17430397.
4. Damman J, Seelen MA, Moers C, Daha MR, Rahmel A, Leuvenink HG, Paul A, Pirenne J, Ploeg RJ. Systemic complement activation in deceased donors is associated with acute rejection after renal transplantation in the recipient. Transplantation 2011, 92:163-169. 10.1097/TP.0b013e318222c9a0, 21677599.
5. Terasaki PI, Cecka JM, Gjertson DW, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med 1995, 333:333-336. 10.1056/NEJM199508103330601, 7609748.
6. Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptin-the classical, resistin-the controversical, adiponectin-the promising, and more to come. Best Pract Res Clin Endocrinol Metab 2005, 19:525-546. 10.1016/j.beem.2005.07.008, 16311215.
7. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006, 6:772-783. 10.1038/nri1937, 16998510.
8. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005, 174:5789-5795.
9. Jung HS, Park KH, Cho YM, Chung SS, Cho HJ, Cho SY, Kim SJ, Kim SY, Lee HK, Park KS. Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc Res 2006, 69:76-85. 10.1016/j.cardiores.2005.09.015, 16271710.
10. Gomez R, Conde J, Scotece M, Gomez-Reino JJ, Lago F, Gualillo O. What's new in our understanding of the role of adipokines in rheumatic diseases?. Nat Rev Rheumatol 2011, 7:528-536. 10.1038/nrrheum.2011.107, 21808287.
11. Wagsater D, Mumtaz M, Lofgren S, Hugander A, Dimberg J. Resistin in human colorectal cancer: increased expression independently of resistin promoter -420C > G genotype. Cancer Invest 2008, 26:1008-1014. 10.1080/07357900802087267, 18798067.
12. Filkova M, Haluzik M, Gay S, Senolt L. The role of resistin as a regulator of inflammation: Implications for various human pathologies. Clin Immunol 2009, 133:157-170. 10.1016/j.clim.2009.07.013, 19740705.
13. Yagmur E, Trautwein C, Gressner AM, Tacke F. Resistin serum levels are associated with insulin resistance, disease severity, clinical complications, and prognosis in patients with chronic liver diseases. Am J Gastroenterol 2006, 101:1244-1252. 10.1111/j.1572-0241.2006.00543.x, 16771945.
14. Konrad A, Lehrke M, Schachinger V, Seibold F, Stark R, Ochsenkuhn T, Parhofer KG, Goke B, Broedl UC. Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol 2007, 19:1070-1074. 10.1097/MEG.0b013e3282f16251, 17998831.
15. Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 2003, 309:286-290. 10.1016/j.bbrc.2003.07.003, 12951047.
16. Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem Biophys Res Commun 2005, 334:1092-1101. 10.1016/j.bbrc.2005.06.202, 16039994.
17. Sunden-Cullberg J, Nystrom T, Lee ML, Mullins GE, Tokics L, Andersson J, Norrby-Teglund A, Treutiger CJ. Pronounced elevation of resistin correlates with severity of disease in severe sepsis and septic shock. Crit Care Med 2007, 35:1536-1542. 10.1097/01.CCM.0000266536.14736.03, 17452927.
18. Koch A, Gressner OA, Sanson E, Tacke F, Trautwein C. Serum resistin levels in critically ill patients are associated with inflammation, organ dysfunction and metabolism and may predict survival of non-septic patients. Crit Care 2009, 13:R95. 10.1186/cc7925, 2717467, 19545363.
19. Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, Mickle DA. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003, 108:736-740. 10.1161/01.CIR.0000084503.91330.49, 12874180.
20. Scherpereel A, Depontieu F, Grigoriu B, Cavestri B, Tsicopoulos A, Gentina T, Jourdain M, Pugin J, Tonnel AB, Lassalle P. Endocan, a new endothelial marker in human sepsis. Crit Care Med 2006, 34:532-537. 10.1097/01.CCM.0000198525.82124.74, 16424738.
21. Vilar E, Varagunam M, Yaqoob MM, Raftery M, Thuraisingham R. Creatinine reduction ratio: a useful marker to identify medium and high-risk renal transplants. Transplantation 2010, 89:97-103. 10.1097/TP.0b013e3181be3dd1, 20061925.
22. Hall IE, Yarlagadda SG, Coca SG, Wang Z, Doshi M, Devarajan P, Han WK, Marcus RJ, Parikh CR. IL-18 and urinary NGAL predict dialysis and graft recovery after kidney transplantation. J Am Soc Nephrol 2010, 21:189-197. 10.1681/ASN.2009030264, 2799276, 19762491.
23. Zhang SM, Zuo L, Zhou Q, Gui SY, Shi R, Wu Q, Wei W, Wang Y. Expression and distribution of endocan in human tissues. Biotech Histochem 2012, 87:172-178. 10.3109/10520295.2011.577754, 21526908.
24. van Dullemen LF, Bos EM, Schuurs TA, Kampinga HH, Ploeg RJ, van Goor H, Leuvenink HG. Brain death induces renal expression of heme oxygenase-1 and heat shock protein 70. J Transl Med 2013, 11:22. 10.1186/1479-5876-11-22, 3568717, 23356498.
25. Schwarz C, Regele H, Steininger R, Hansmann C, Mayer G, Oberbauer R. The contribution of adhesion molecule expression in donor kidney biopsies to early allograft dysfunction. Transplantation 2001, 71:1666-1670. 10.1097/00007890-200106150-00028, 11435980.
26. Ogliari AC, Caldara R, Socci C, Sordi V, Cagni N, Moretti MP, Dell'acqua A, Mercalli A, Scavini M, Secchi A, et al. High levels of donor CCL2/MCP-1 predict graft-related complications and poor graft survival after kidney-pancreas transplantation. Am J Transplant 2008, 8:1303-1311. 10.1111/j.1600-6143.2008.02240.x, 18444915.
27. Reynaud-Gaubert M, Marin V, Thirion X, Farnarier C, Thomas P, Badier M, Bongrand P, Giudicelli R, Fuentes P. Upregulation of chemokines in bronchoalveolar lavage fluid as a predictive marker of post-transplant airway obliteration. J Heart Lung Transplant 2002, 21:721-730. 10.1016/S1053-2498(02)00392-3, 12100898.
28. Tarkowski A, Bjersing J, Shestakov A, Bokarewa MI. Resistin competes with lipopolysaccharide for binding to toll-like receptor 4. J Cell Mol Med 2010, 14:1419-1431.
29. Dong XQ, Hu YY, Yu WH, Zhang ZY. High concentrations of resistin in the peripheral blood of patients with acute basal ganglia hemorrhage are associated with poor outcome. J Crit Care 2010, 25:243-247. 10.1016/j.jcrc.2009.09.008, 19903588.
30. Dong XQ, Yang SB, Zhu FL, Lv QW, Zhang GH, Huang HB. Resistin is associated with mortality in patients with traumatic brain injury. Crit Care 2010, 14:R190. 10.1186/cc9307, 3219297, 21029428.
31. Efstathiou SP, Tsiakou AG, Tsioulos DI, Panagiotou TN, Pefanis AV, Achimastos AD, Mountokalakis TD. Prognostic significance of plasma resistin levels in patients with atherothrombotic ischemic stroke. Clin Chim Acta 2007, 378:78-85. 10.1016/j.cca.2006.10.023, 17173885.
32. Axelsson J, Bergsten A, Qureshi AR, Heimburger O, Barany P, Lonnqvist F, Lindholm B, Nordfors L, Alvestrand A, Stenvinkel P. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int 2006, 69:596-604. 10.1038/sj.ki.5000089, 16395259.
33. Almehed K, d'Elia HF, Bokarewa M, Carlsten H. Role of resistin as a marker of inflammation in systemic lupus erythematosus. Arthritis Res Ther 2008, 10:R15. 10.1186/ar2366, 2374439, 18234104.
34. Kielstein JT, Becker B, Graf S, Brabant G, Haller H, Fliser D. Increased resistin blood levels are not associated with insulin resistance in patients with renal disease. Am J Kidney Dis 2003, 42:62-66. 10.1016/S0272-6386(03)00409-8, 12830457.
35. Murugan R, Venkataraman R, Wahed AS, Elder M, Hergenroeder G, Carter M, Madden NJ, Powner D, Kellum JA. Increased plasma interleukin-6 in donors is associated with lower recipient hospital-free survival after cadaveric organ transplantation. Crit Care Med 2008, 36:1810-1816. 10.1097/CCM.0b013e318174d89f, 18496370.
36. Damman J, Daha MR, van Son WJ, Leuvenink HG, Ploeg RJ, Seelen MA. Crosstalk between complement and Toll-like receptor activation in relation to donor brain death and renal ischemia-reperfusion injury. Am J Transplant 2011, 11:660-669. 10.1111/j.1600-6143.2011.03475.x, 21446970.
37. Alakulppi NS, Kyllonen LE, Jantti VT, Matinlauri IH, Partanen J, Salmela KT, Laine JT. Cytokine gene polymorphisms and risks of acute rejection and delayed graft function after kidney transplantation. Transplantation 2004, 78:1422-1428. 10.1097/01.TP.0000140884.71571.BC, 15599305.
38. Hollmen ME, Kyllonen LE, Inkinen KA, Lalla ML, Merenmies J, Salmela KT. Deceased donor neutrophil gelatinase-associated lipocalin and delayed graft function after kidney transplantation: a prospective study. Crit Care 2011, 15:R121. 10.1186/cc10220, 3218974, 21545740.
39. Humar A, Ramcharan T, Kandaswamy R, Gillingham K, Payne WD, Matas AJ. Risk factors for slow graft function after kidney transplants: a multivariate analysis. Clin Transplant 2002, 16:425-429. 10.1034/j.1399-0012.2002.02055.x, 12437622.
40. Yarlagadda SG, Coca SG, Garg AX, Doshi M, Poggio E, Marcus RJ, Parikh CR. Marked variation in the definition and diagnosis of delayed graft function: a systematic review. Nephrol Dial Transplant 2008, 23:2995-3003. 10.1093/ndt/gfn158, 2727302, 18408075.
41. Otukesh H, Hosein R, Fereshtehnejad SM, Riahifard A, Basiri A, Simforoosh N, Chalian M, Jazayeri S, Chalian H, Safarzadeh AE, et al. Short-term and long-term effects of slow graft function on graft survival in pediatric live donor renal transplantation. Pediatr Transplant 2010, 14:196-202. 10.1111/j.1399-3046.2009.01191.x, 19496981.
42. Port FK, Bragg-Gresham JL, Metzger RA, Dykstra DM, Gillespie BW, Young EW, Delmonico FL, Wynn JJ, Merion RM, Wolfe RA, Held PJ. Donor characteristics associated with reduced graft survival: an approach to expanding the pool of kidney donors. Transplantation 2002, 74:1281-1286. 10.1097/00007890-200211150-00014, 12451266.